Well yes. BMS paid US$1.85 billion as an upfront payment, not a takeover, with Nektar. Then there is billions in milestone payments. And here Merck offers a quarter of that for the whole company.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025